Merck & Co. Inc. (NYSE: MRK) Thursday reported an increase in adjusted earnings for the first quarter of 2025, while the pharma company’s sales declined modestly. First-quarter sales were $15.5 billion, compared to $15.8 billion in the prior year quarter. Pharmaceutical sales declined by 3% while Animal Health sales grew by 5%. The company reported adjusted […]
“Merck & Co. Inc. (NYSE: MRK) Thursday reported an increase in adjusted earnings for the first quarter of 2025, while the pharma company’s sales declined modestly. First-quarter sales were $15.5 billion, compared to $15.8 billion in the prior year quarter. Pharmaceutical sales declined by 3% while Animal Health sales grew by 5%. The company reported adjusted […]
· April 24, 2025
Merck & Co. Inc. (NYSE: MRK) Thursday reported an increase in adjusted earnings for the first quarter of 2025, while the pharma company’s sales declined modestly.
First-quarter sales were $15.5 billion, compared to $15.8 billion in the prior year quarter. Pharmaceutical sales declined by 3% while Animal Health sales grew by 5%.
The company reported adjusted earnings of $2.22 per share for the first quarter, compared to $2.07 per share in Q1 2024. The latest number topped expectations. Net profit was $5.08 billion or $2.01 per share in the March quarter, compared to $4.76 billion or $1.87 per share in the same period of last year.
